Literature DB >> 3140658

Chronic T cell lymphoproliferative disorder and pure red cell aplasia. Further characterization of cell-mediated inhibition of erythropoiesis and clinical response to cytotoxic chemotherapy.

L P Akard1, J Brandt, L Lu, J Jansen, R Hoffman.   

Abstract

Two patients with pure red cell aplasia and a T cell lymphoproliferative disorder were studied in order to define the mechanism of suppression of erythropoiesis and the patients' response to cytotoxic therapy. In vitro assays demonstrated enhanced formation of both erythroid colonies and bursts following T-cell depletion. Erythroid colony formation was suppressed by the readdition of autologous T cells to a null cell fraction of marrow mononuclear cells. Media conditioned by the patients' T cells did not exhibit any inhibitory effect on erythroid colony formation by autologous T cell-depleted marrow cells. These in vitro results suggested that T cell-mediated suppression of erythropoiesis was responsible for the generation of pure red cell aplasia. In both patients, cyclophosphamide therapy resulted in clinical remissions manifested by normalization of the hematocrits associated with a reduction in circulating lymphocytes from more than 10,000/mm3 to under 500/mm3. Maintenance chemotherapy has caused persistent inhibition of lymphocyte counts along with durable remissions with normal hematocrits.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3140658     DOI: 10.1016/0002-9343(87)90943-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

1.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 2.  Autoimmune cytopenias in chronic lymphocytic leukemia.

Authors:  Giovanni D'Arena; Roberto Guariglia; Francesco La Rocca; Stefania Trino; Valentina Condelli; Laura De Martino; Vincenzo De Feo; Pellegrino Musto
Journal:  Clin Dev Immunol       Date:  2013-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.